Leerink Partnrs Has Bullish Outlook for Vericel Q4 Earnings

Vericel Co. (NASDAQ:VCEL) – Analysts at Leerink Partnrs increased their Q4 2025 earnings per share (EPS) estimates for Vericel in a report released on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now forecasts that the biotechnology company will earn $0.48 per share for the quarter, up from their prior forecast of $0.45. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel’s FY2029 earnings at $2.76 EPS.

VCEL has been the subject of a number of other reports. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial reduced their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a report on Friday, April 11th. Canaccord Genuity Group upped their target price on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a report on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Friday, February 28th. Finally, StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a research note on Monday. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $60.86.

Vericel Trading Up 2.3%

VCEL stock opened at $43.64 on Monday. The company’s 50-day moving average price is $42.91 and its 200 day moving average price is $51.21. Vericel has a 52 week low of $37.39 and a 52 week high of $63.00. The company has a market cap of $2.19 billion, a P/E ratio of 727.45 and a beta of 1.31.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). The company had revenue of $52.60 million for the quarter, compared to analysts’ expectations of $53.86 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Vericel’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) earnings per share.

Institutional Investors Weigh In On Vericel

Hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. raised its position in shares of Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 183 shares during the last quarter. Atria Investments Inc grew its stake in Vericel by 2.4% in the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 184 shares during the period. Captrust Financial Advisors raised its holdings in Vericel by 3.4% in the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 199 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after purchasing an additional 200 shares during the period. Finally, Avantax Advisory Services Inc. boosted its holdings in shares of Vericel by 1.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock worth $758,000 after purchasing an additional 234 shares during the last quarter.

Insider Activity

In related news, CEO Dominick Colangelo sold 24,850 shares of Vericel stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the completion of the sale, the chief executive officer now owns 260,354 shares in the company, valued at approximately $10,906,229.06. This trade represents a 8.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.